Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial

Condition tags

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (23)

• Integrated Pharmacometrics and Systems Pharmacology Model‐Based Analyses to Guide GnRH Receptor Modulator Development for Management of Endometriosis 2012
• Serum levels of estradiol and follicle stimulating hormone,and vasomotor symptoms in Thai women receivingGnRH analogue before laparoscopic enucleationof endometriotic cysts 2012
• The efficacy and tolerability of short-term low-dose estrogen-only add-back therapy during post-operative GnRH agonist treatment for endometriosis 2010
• Bone Density in Adolescents Treated with a GnRH Agonist and Add-Back Therapy for Endometriosis 2007
• GnRH analogs: Options for endometriosis-associated pain treatment 2006
• Avances en el tratamiento quirúrgico de la endometriosis 2004
• Endometriosis 2003
• Tratamiento de la endometriosis y medicina basada en la evidencia 2003
• The Treatment of Endometriosis 2002
• HRT as add-back therapy 2002
• Treatment of Endometriosis 2001
• UPDATE ON THE MEDICAL TREATMENT OF ENDOMETRIOSIS 2000
• Medical management of endometriosis 2000
• Estrogen and lipid profile in patients with endometriosis treated by GnRH agonist 1999
• GnRH agonists and add‐back therapy: is there a perfect combination? 1998
• Endometriosis and Pelvic Pain 1998
• MODERN MEDICAL MANAGEMENT OF ENDOMETRIOSIS 1997
• Long-term follow-up on the treatment of endometriosis with the GnRH-agonist buserelinacetate Long-term follow-up data (up to 98 months) of 42 patients with endometriosis who were treated with GnRH-agonist buserelinacetate (Suprecur®), were evaluated in respect of recurrence of pain symptoms and pregnancy outcome 1997
• Combined use of a long-acting gonadotropin-releasing hormone agonist and low-dose danazol in advanced stage endometriosis 1996
• Pain recurrence: A quality of life issue in endometriosis 1995
• Goserelin (Zoladex) and the skeleton 1994
• Nafarelin therapy in endometriosis: Long-term effects on bone mineral density 1994
• Medical management of endometriosis 1993

Source provenance

openalex

last seen: 2026-06-10T17:14:06.276822+00:00